We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immunogenicity and Safety of CoronaVac Vaccine in Elderly Cancer Patients Receiving Cytotoxic Chemotherapy.
- Authors
YILMAZ, Bahiddin; GUR VURAL, Demet; ISIK BAYRAKTAR, Demet; DEMIR, Ozden; ALAN, Murat; AYDIN, Mesut; BIRINCI, Asuman
- Abstract
The aim of our study to evaluate the immunogenicity and safety of inactivated CoronaVac vaccine in elderly cancer patients actively receiving cytotoxic chemotherapy. This single-center, prospective cohort study was conducted with 42 patients older than 65 years receiving cytotoxic chemotherapy and 43 healthy volunteers. CoronaVac vaccine was administered to both groups as two doses (3 µg/day) on days 0 and 28. Antibody levels measured after 28 days (+/-3 days) from second dose of vaccine and = 1 U/mL were considered positive. Antibody seropositivity was detected in all the controls (n= 43, 100%). Of the 42 patients, seropositivity was detected in 32 (76.2%) cases (p< 0.001). The median antibody level was significantly lower in the patient group than in the control group (21.6 U/ml vs 51.7 U/ml respectively, p= 0.011). SARS-CoV-2 infection was detected in five of the 42 cancer patients and none of the control group. None of the patients who tested positive for COVID-19 had pulmonary involvement, and none of the patients died due to SARS-CoV-2 infection. Despite of the developed poor immune response than healthy adults, CoronaVac vaccine was effective and safe in elderly cancer patients with actively receiving cytotoxic chemotherapy.
- Subjects
OLDER patients; CANCER chemotherapy; CANCER vaccines; CANCER patients; IMMUNE response
- Publication
UHOD: International Journal of Hematology & Oncology / Uluslararasi Hematoloji Onkoloji Dergisi, 2023, Vol 33, Issue 2, p103
- ISSN
1306-133X
- Publication type
Article
- DOI
10.4999/uhod.236571